financetom
Business
financetom
/
Business
/
Arm's quarterly revenue forecast beats Street; annual rev guidance misses
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Arm's quarterly revenue forecast beats Street; annual rev guidance misses
May 8, 2024 1:23 PM

(Reuters) -Chip designer Arm Holdings gave a fiscal first-quarter revenue forecast on Wednesday that beat Wall Street's expectations, but its full-year forecast was below expectations.

Shares of Arm fell about 4% in extended trading after the report.

For the current fiscal first quarter, Arm forecast revenue in a range between $875 million and $925 million, with a midpoint of $900 million, compared with an average analyst estimate of $857.5 million, according to LSEG data.

The UK chip designer also said it expects full-year revenue between $3.8 billion and $4.1 billion, with a midpoint of $3.95 billion. That compares with a consensus estimate of $3.99 billion.

Arm's fourth-quarter revenue rose 47% to $928 million, compared with analyst estimates of $875.6 million.

It reported fourth-quarter earnings of 36 cents per share, adjusted for stock-based compensation, among other things.

Arm generates revenue from licensing fees for its semiconductor designs and collects a royalty for each chip sold that uses its technology.

Bets that Arm will benefit from a surge in artificial-intelligence computing have doubled the chipmaker's share price since its initial public offer last September, giving it market value of about $110 billion. The shares recently traded at nearly 70 times expected earnings, compared with 35 times earnings for heavyweight chipmaker Nvidia, according to LSEG data.

Arm's designs power nearly every smartphone in the world, and the company has attempted to make headway in data centers and other markets. Chips with Arm technology generate $200 billion a year of revenue for the many chipmakers that sell them, according to research from TD Cowen.

Though Arm's designs are found adjacent to chips that power AI applications, the company's revenue and profit have not benefited from AI to the same degree as Nvidia's.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
TRxADE Health, Scienture Complete Business Combination; TRxADE Shares Jump
TRxADE Health, Scienture Complete Business Combination; TRxADE Shares Jump
Jul 26, 2024
11:20 AM EDT, 07/26/2024 (MT Newswires) -- TRxADE Health ( MEDS ) and Scienture said Friday they have completed their all-stock business combination valued at $103 million. Under the deal, TRxADE acquired Scienture's assets in exchange for common stock and non-voting convertible preferred stock and will rebrand as Scienture Holdings and continue to trade on Nasdaq. Scienture stockholders will own...
Apple signs on to voluntary US scheme to manage AI risks, White House says
Apple signs on to voluntary US scheme to manage AI risks, White House says
Jul 26, 2024
WASHINGTON, July 26 (Reuters) - Apple Inc ( AAPL ) has signed U.S. President Joe Biden's voluntary commitments governing artificial intelligence (AI), joining 15 other firms that have committed to ensuring that AI's power is not used for destructive purposes, the White House said on Friday. The original commitments, announced in July 2023, were signed on to by firms including...
Geron's Rytelo Gets NCCN Recommendation for Treatment of Symptomatic Anemia in Myelodysplastic Syndromes
Geron's Rytelo Gets NCCN Recommendation for Treatment of Symptomatic Anemia in Myelodysplastic Syndromes
Jul 26, 2024
11:15 AM EDT, 07/26/2024 (MT Newswires) -- Geron ( GERN ) said Friday that the National Comprehensive Cancer Network updated its guidelines to recommend Rytelo, or imetelstat, as a Category 1 and 2A treatment for symptomatic anemia in lower-risk myelodysplastic syndromes. The Category 1 recommendation is for second-line treatment after Bristol-Myers Squibb's ( BMY ) Reblozyl, or luspatercept, in patients...
Truist Securities on Waste Connections' Outlook
Truist Securities on Waste Connections' Outlook
Jul 26, 2024
11:17 AM EDT, 07/26/2024 (MT Newswires) -- Waste Connections ( WCN ) reported upside second quarter results and raised 2024 guidance primarily due to another active M&A quarter (bought ~$275 million in annual revenue), notes Truist Securities. We think WCN is poised to message another year of outsized margin expansion in 2025 next quarter with easier volume comps and persistent...
Copyright 2023-2026 - www.financetom.com All Rights Reserved